RECRUITING HAEMATOLOGY TRIALS
Last Updated 21 February 2024 4.00 PM
GCT3013-02
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
CURRENT SLOT STATUS
Available
PHASE
Phase I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
POD24 FL
R/R DLBCL eligible for ASCT
IP CLASS
Targeted
PRT2527-02
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies
CURRENT SLOT STATUS
Available
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
CDK9 Inhibitor
DZ2022B0002
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
CURRENT SLOT STATUS
Available
PHASE
Phase I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
BTKi
SLN124-004
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
CURRENT SLOT STATUS
Available
PHASE
I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
PV
IP CLASS
siRNA
BGB-16673-101
A Phase I/Ib Open-Label Dose Escalation and Expansion Study of Bel-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
CURRENT SLOT STATUS
Available
PHASE
I/Ib
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
BCL-2 Inhibitor + BTKi, Targeted
218670 (DREAMM20)
A Phase 1/2 open-label, multicentre, dose escalation and expansion study to investigate the safety, tolerability, and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma.
CURRENT SLOT STATUS
Waitlist
PHASE
I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
MM
IP CLASS
Anti BCMA Antibody/ADC +/- SOC Therapies
MoST 16 Pamiparib
Single arm, open label, signal seeking, phase II trial of pamiparib in patients with relapsed/refractory myeloid haematological malignancy with aberrant germline or somatic DNA repair pathway function.
CURRENT SLOT STATUS
Available
PHASE
II
REQUIRED MOLECULAR TARGET
DNA Repair Pathway Mutation
TUMOUR TYPES
AML, MDS
IP CLASS
PARP Inhibitor
BGB-11417-103
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
CURRENT SLOT STATUS
Waitlist
PHASE
Ia/Ib
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
AML, MDS
IP CLASS
BCL-2 Inhibitor
80948543LYM1001
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
CURRENT SLOT STATUS
Waitlist
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
Trispecific
87801493LYM1001
A Phase 1, First-in-human Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
CURRENT SLOT STATUS
Available
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL
IP CLASS
Trispecific Antibody OR Bispecific Antibody + Bispecific Co-Stimulatory Antibody
BGB-11417-101
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
CURRENT SLOT STATUS
Available
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
BCL-2 Inhibitor + BTK inhibitor
DR-01-ONC-001
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
CURRENT SLOT STATUS
Available
PHASE
I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
T-Cell Lymphoma, LGLL
IP CLASS
Targeted
IMpress_001
A phase II study evaluating the efficacy and safety of imetelstat in patients with HR myelodysplastic syndromes or AML failing HMA-based therapy
CURRENT SLOT STATUS
Waitlist
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
AML, HR MDS
IP CLASS
Telomerase Inhibitor
IKS03-01
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03, a CD19-Targeting Antibody Drug Conjugate (ADC), in Patients with Advanced B cell Non-Hodgkin Lymphomas (NHL).
CURRENT SLOT STATUS
Available
PHASE
I
REQUIRED MOLECULAR TARGET
CD19 Positive (if feasible)
TUMOUR TYPES
NHL
IP CLASS
CD19 ADC
ISB 2001-101
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
CURRENT SLOT STATUS
Available
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
MM
IP CLASS
CD3xCD38xBCMA Trispecific
ASTX660-03
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
CURRENT SLOT STATUS
Available
PHASE
Phase I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
PTCL
IP CLASS
AP Antagonist + Hypomethalation Agent/CDA Inhibitor
BGB-21447-101
A Phase 1, Open-Label Dose Escalation Study of Bcl-2 inhibitor BGB-21447 in Patients with Mature B-Cell Malignancies
CURRENT SLOT STATUS
Opening Soon
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
BCL-2 Inhibitor
D7230C00001
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Refractory Multiple Myeloma.
CURRENT SLOT STATUS
Available
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
MM
IP CLASS
GPRC5D ADC